Health Canada says three companies are voluntarily recalling all lots of the antipsychotic drug quetiapine.

A Health Canada news release says it's due to potential contamination with the antibiotic product clindamycin during the manufacturing process.

Health Canada says quetiapine is used in the treatment of schizophrenia and bipolar disorder in adult patients.

Health Canada says it has not received any reports of adverse reactions from the product.

The government says those at risk includes people who are susceptible or hypersensitive to the antibiotics clindamycin or lincomycin.

Health Canada says the possibility of contamination was spotted at the pharmaceutical factory in China that produces quetiapine for the three companies — Cobalt Pharmaceuticals Company, Laboratoires Riva and Sanis Health.

Health Canada says the products affected include all lots of 25 mg, 100 mg, 200 mg and 300 mg doses of Co Quetiapine (Cobalt Pharmaceuticals Company), Riva Quetiapine (Laboratoires Riva), and Sanis Quetiapine (Sanis Health)